Who are Ocrelizumab (CinnaGen, Iran)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Venetoclax; Rituximab, Columvi, Lunsumio, Ocrevus, Gazyva, Kesimpta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ocrelizumab-cinnagen-iran.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ocrelizumab (CinnaGen, Iran) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ocrelizumab (CinnaGen, Iran) (Ocrelizumab (CinnaGen, Iran)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD20-targeting monoclonal antibody. Area: Immunology.

phase 3 CD20-targeting monoclonal antibody CD20 Immunology Biologic Live · refreshed every 30 min

Target snapshot

Ocrelizumab (CinnaGen, Iran) (Ocrelizumab (CinnaGen, Iran)) — Cinnagen. Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ocrelizumab (CinnaGen, Iran) TARGET	Ocrelizumab (CinnaGen, Iran)	Cinnagen	phase 3	CD20-targeting monoclonal antibody	CD20
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Columvi	glofitamab	Roche	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	B-lymphocyte antigen CD20	2023-01-01
Lunsumio	MOSUNETUZUMAB	Roche	marketed		B-lymphocyte antigen CD20	2022-01-01
Ocrevus	OCRELIZUMAB	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2017-01-01
Gazyva	obinutuzumab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2013-01-01
Kesimpta	OFATUMUMAB	Novartis	marketed	Anti-CD20 monoclonal antibody	CD20	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD20-targeting monoclonal antibody class)

Sandoz · 3 drugs in this class
Hoffmann-La Roche · 3 drugs in this class
Cinnagen · 1 drug in this class
Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
Genentech, Inc. · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
Rennes University Hospital · 1 drug in this class
Amgen · 1 drug in this class
University Hospital, Toulouse · 1 drug in this class
Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ocrelizumab (CinnaGen, Iran) — Competitive Intelligence Brief. https://druglandscape.com/ci/ocrelizumab-cinnagen-iran. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab